Africa grabs hold of mRNA technology
Welcome to What Could Go Right?, a free weekly newsletter from?The Progress Network?written by our executive director, Emma Varvaloucas. In addition to this newsletter, which collects substantive progress news from around the world, The Progress Network publishes an?anti-apocalypse conversational podcast also called What Could Go Right?.
We say the world has made remarkable progress, you say show us the receipts.?Sign up to receive this newsletter by email, and we'll send you our reading and listening guide to all the things in the world that have improved in just the past few decades.
mRNA technology comes to Africa
In a move that bolsters their bottom line but likely prolongs the pandemic, mRNA vaccine makers Moderna, Pfizer, and BioNTech have refused to share the necessary technology for their Covid-19 vaccines with low- and middle-income countries, forcing them to pay for doses at a premium or wait for donated ones rather than produce their own. It has contributed to a tale of two worlds: “Countries and regions with the highest incomes,” according to the?Bloomberg?vaccine tracker, “are getting vaccinated more than 10 times faster than those with the lowest.”
But this week, the South Africa-based biotechnology company Afrigen Biologics and Vaccines, with an assist from the World Health Organization (WHO) and funds from Europe, announced that they had?successfully created their own mRNA vaccine, developed from Moderna’s vaccine sequence. (Moderna patented the sequence, but Stanford University researchers uploaded it to a public database in spring last year, and Moderna has pledged not to enforce the patent during the pandemic.) Afrigen is a hub in the WHO’s “mRNA tech-transfer” initiative, which is meant to boost the ability of countries without mRNA technology to access it, pass it among themselves, and ultimately build out vaccine manufacturing capacity. When the initiative launched in June 2021, the WHO reached out to Moderna, Pfizer, and BioNTech for direction guiding their initiative’s global researchers, but none came.
“We didn’t have help from the major Covid-vaccine producers,” Afrigen chief scientist Gerhardt Boukes told?Nature, “so we did it ourselves to show the world that it can be done, and be done here, on the African continent.”
The South African development has come too late to be a major factor in ending the pandemic. Phase 1 human trials aren’t expected to start until November. But it’s a foundational?step toward?African and other countries' vaccine-independence, and toward ensuring?that whatever future benefits mRNA brings, they will not be solely concentrated in the wealthy West. As part of the initiative, companies throughout the global south will now attempt to repeat Afrigen’s success. We wish them the best.
Spray the Covid away
Indian pharmaceutical company Bharat Biotech is experimenting with a?Covid vaccine that would be sprayed into the nose, in a potential win for the needle-averse everywhere. Several other nasal Covid vaccines are also in development, but?The New York Times?thinks that Bharat’s may be the first to become available. It’s currently in Phase 3 trials in India as a booster dose.
Because nasal vaccines “coat the mucosal surfaces of the nose, mouth, and throat,” where the virus first lands, “with long-lasting antibodies,” they may perform better than the injectable vaccines at preventing infection. They are also easier to administer and disseminate, a speed advantage that could prove crucial in a future wave.
And if you haven’t had enough science reads for today,?MIT Technology Review?has an?exciting piece on Pfizer’s Covid antiviral, Paxlovid, which was a slightly less heralded, but no less triumphant achievement than the various vaccines. The pill, which is highly effective at preventing serious illness if taken within five days of infection, is currently in short supply. But it won’t be forever, and when it’s more plentiful, you’ll be able to grab it at your local pharmacy. (Also, data from Pfizer suggests that the pill will “work against all coronaviruses, maybe even one still lurking in a bat cave somewhere.”)?
For all the criticism of governments not preparing for future pandemics, over the summer, the United States did commit $3 billion to antiviral research on everything from corona to Ebola. The idea is to have workable pills ready to go before we actually need them. That does sound nice.
You better werk . . . to make workplaces safer for women
If you saw?Bombshell, the 2019 movie about?the sexual harassment allegations against former Fox News?CEO Roger Ailes, then you know the devilry of the forced arbitration clause that is lurking in many work contracts. Signing a contract with this clause means that you’ve signed away your right to make a misconduct claim public in court, instead agreeing to a “private proceeding with [an] employer. . . . a process that takes place in secret, led by company-appointed arbitrators, and without the ability to appeal the result,” reports?The New York Times. Beholden to this?process, perpetrators remain unnamed, and claimants lack leverage to win appropriately sized settlements.?
On Monday, the US House?passed legislation that would end the use of forced arbitration clauses in workplace sexual harassment and assault cases. (It is expected to pass the Senate and be signed by President Biden.) And how’s this for a story of cooperation across party lines: this all happened because activism by former Fox celebrity Gretchen Carlson caught the attention of North Carolina Republican Senator Lindsey Graham, who then scooped up New York Democratic Senator Kirsten Gillibrand to work on the bill together. It passed the House 335 to 97.
Pakistan is making changes, too. Last month their parliament passed a law that will?better protect women against workplace harassment. The bill widened the definition of what constitutes harassment as well as what is considered a workplace, so that domestic workers and other women in “informal” work environments?are included. Students, a category previously excluded, are also now protected.?
Before we go
You can smoke that good stuff—with a valid medical reason—even in Mississippi.?The Magnolia State greenlit medical marijuana yesterday, becoming the 37th state to do so.?
Emissions dipped during the pandemic as trade and industry halted. We always knew they would come back, but we didn’t know by how much. Turns out it’s less than we expected.?Bloomberg’s green energy newsletter on the?signs that the global economy is getting less carbon intensive over time here. And,?new efforts to make a “circular car,”?which would eliminate waste through the car’s entire lifespan.
Gene editing galore—what to expect in neuroscience, genetics, longevity, biotech, and psychedelics in 2022?from?Neo.Life.
领英推荐
There have been several interesting early-stage medical advancements this week that we didn’t have space to include. Stay tuned for those stories next week!
Below in the links section,?a?cutting-edge cancer treatment, a fashion giant is going furless, offshore wind farms may have another trick up their sleeves, and more.
—Emma Varvaloucas
New from the Progress Network
Bonus Podcast Episode: The Population Explosion
Are we on the brink of a population explosion with untold global consequences? On the contrary, a growing number of experts argue that we are headed for a worldwide decline. Hear from?Empty Planet?authors John Ibbitson and Darrell Bricker on how this could bring with it many benefits as well as surprising disruptions. This recording was first released on March 5th, 2019. |?Listen to the episode
Other good stuff in the news
Found good news we should hear about? Drop a link in the comments!
United States:
International:
TPN Member?originals??
See how many clicks it takes to get to the center of our?long list of the week's progress links.
Upcoming Events
Libero professionista Commercio internazionale e Sviluppo dei Tecnici per concetto 'FAMIGLIETTA'.
2 年Good do !! ?? ?? ?? ?? ?? ??
DER BUNTE VOGEL ?? Internationaler Wissenstransfer - Influencerin bei Corporate Influencer Club | Wirtschaftswissenschaften
2 年Thank you Zachary Karabell - welcome ??